The estimated prevalence in Greece ranges between 0.35 to 0.68%,3–5 a finding that is concordant with the estimates from other Mediterranean countries.6 Regarding current therapies, in the largest Greek study so far conducted by the Hellenic Registry of Biologics, 1.028 RA patients treated with tumor necrosis factor (TNF) inhibitors (TNFi) were included.7 The primary purpose of the study was to evaluate the drug survival and the serious complications of TNFi during long-term follow-up (2004–2009). This evidence concerns the gene TNF and rheumatoid arthritis.